Abstract 5407: MicroRNA expression analysis of advanced colorectal cancer reveals a microRNA signature with prognostic and predictive value

Zhaolei Zeng,Jiahua Lu,Zhixiang Zuo,Qi Zhao,Ruihua Xu

DOI: https://doi.org/10.1158/1538-7445.am2018-5407

IF: 11.2

2018-01-01

Cancer Research

Abstract:Background Prognostic and predictive markers are needed to predict the clinical outcomes of patients with advanced colorectal cancer (CRC) who receive standard first-line treatments. We performed a prospective cohort study in patients with advanced CRC to identify a miRNA signature that could predict the benefit of receiving first-line chemotherapy for these patients. Methods Twenty-one paired tumours and adjacent normal tissues were collected from patients with advanced CRC and analysed by miRNA microarrays. Between tumour and normal tissues, 33 miRNAs were differentially expressed. The differential expression of these miRNAs was confirmed by qRT-PCR using paraffin-embedded specimens from another group of 76 patients from a prospective cohort study. A two-miRNA-based signature was obtained using the least absolute shrinkage and selection operator (LASSO) Cox regression model based on the association between the expression of each miRNA and the progression-free survival (PFS) time of individual patients. Internal and external validation cohorts, including 45 and 50 patients with advanced CRC, respectively, were performed to validate the prognostic and predictive accuracy of this signature. Results A signature based on two miRNAs, miR-125b-2-3p and miR-933, was built by the LASSO model. CRC patients were classified into high- and low-risk groups for disease progression based on this tool. The patients with high risk scores generally had worse PFS than those with lower risk scores. In the training set, the average PFS was 23.906 months for the low-risk group and 9.010 months for the high-risk group (hazard ratio [HR] 2.535, 95% CI 1.478-4.348, p=0.001). In the internal validation set, the average PFS was 14.029 months for the low-risk group and 6.334 months for the high-risk group (HR 3.173, 95% CI 1.415-7.116, p=0.005). In the external validation set, the average PFS was 16.815 months for the low-risk group and 7.657 months for the high-risk group (HR 2.498, 95% CI 1.281-4.871, p=0.007). Furthermore, we detected miR-125b-2-3p associated with CRC cell sensitivity to first-line chemotherapy. The two-miRNA-based signature was an independent prognostic factor for predicting the outcome of patients with metastatic CRC receiving first-line chemotherapy. Citation Format: Zhaolei Zeng, Jiahua Lu, Zhixiang Zuo, Qi Zhao, Ruihua Xu. MicroRNA expression analysis of advanced colorectal cancer reveals a microRNA signature with prognostic and predictive value [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5407.